High sensitivity-C-reactive protein variability and risk of cancer incidence: A longitudinal prospective cohort study cancer
4 affiliations
- 1Department of General Surgery, Aerospace Center Hospital, Beijing 100049, P.R. China
- 2Department of Intensive Care Medicine, The General Hospital of The Northern Theater Command of The People's Liberation Army of China, Shenyang, Liaoning 110003, P.R. China
- 3Department of Hepatological Surgery, Kailuan General Hospital, North China University of Science and Technology, Tangshan, Hebei 063000, P.R. China
- 4Department of General Surgery, Kailuan General Hospital, North China University of Science and Technology, Tangshan, Hebei 063000, P.R. China
Abstract
The association between inflammation and cancer has been extensively studied. However, studies examining the relationship between the magnitude of inflammatory fluctuations and cancer remain limited. Consequently, the present study aimed to explore the association between high-sensitivity C-reactive protein (hs-CRP) variability and the occurrence of cancer. A total of 42,514 participants were enrolled in the present study, with their hs-CRP levels measured over a 4-year period. The coefficient of variation (CV) of hs-CRP was used to quantify the variability in inflammatory status. Cox regression analysis was used to assess the association between hs-CRP variability and cancer risk after adjusting for potential confounding factors. The results demonstrated that a high CV of hs-CRP was significantly associated with reduced cancer risk [hazard ratio (HR), 0.84; 95% confidence interval (CI), 0.75-0.94]. Participants with high hs-CRP and low CV had a significantly increased risk of cancer (HR, 1.42; 95% CI, 1.18-1.70). In the stratified analysis of tumors at different sites, the association between hs-CRP variability and lung cancer risk was the most pronounced (HR, 0.77; 95% CI, 0.63-0.96). Sensitivity analyses confirmed the stability of the association between hs-CRP variability and cancer. In conclusion, higher hs-CRP variability was associated with lower cancer risk, particularly for lung cancer; however, these findings provide preliminary evidence and require validation in future studies.
Related
- Impact of High-sensitivity C-reactive protein testing on statin use in primary prevention: A national multicenter analysis
- Adjudicator sensitivity of safety estimates in large language models for open-ended cardiovascular reasoning: a blinded multi-adjudicator benchmark study running title: adjudicator variability in LLM safety
- Joint association of the C-reactive protein-triglyceride-glucose index and frailty with incident stroke: a nationwide prospective cohort study
- The weight of pills: medication use and fall incidence in Saudi community-dwelling adults aged 50 years and older: a 10-month longitudinal study
- L-Shaped Association of C-Reactive Protein-Albumin-Lymphocyte Index and COPD Incidence: A Nationwide Cohort Study in the UK Biobank
BibTeX
@article{xu2026high,
title = {{High sensitivity-C-reactive protein variability and risk of cancer incidence: A longitudinal prospective cohort study cancer}},
author = {Guoshuai Xu and Renjia Cheng and Yiming Wang and Xiangming Ma and Qingsong Zhang and Jun Qu and Wenqiang Li},
journal = {Experimental and Therapeutic Medicine},
year = {2026},
month = oct,
doi = {10.3892/etm.2026.13344},
url = {https://europepmc.org/article/PMC/PMC13725645},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - High sensitivity-C-reactive protein variability and risk of cancer incidence: A longitudinal prospective cohort study cancer
AU - Guoshuai Xu
AU - Renjia Cheng
AU - Yiming Wang
AU - Xiangming Ma
AU - Qingsong Zhang
AU - Jun Qu
AU - Wenqiang Li
PY - 2026
DA - 2026/10/26
JO - Experimental and Therapeutic Medicine
DO - 10.3892/etm.2026.13344
UR - https://europepmc.org/article/PMC/PMC13725645
AB - The association between inflammation and cancer has been extensively studied. However, studies examining the relationship between the magnitude of inflammatory fluctuations and cancer remain limited. Consequently, the present study aimed to explore the association between high-sensitivity C-reactive protein (hs-CRP) variability and the occurrence of cancer. A total of 42,514 participants were enrolled in the present study, with their hs-CRP levels measured over a 4-year period. The coefficient of variation (CV) of hs-CRP was used to quantify the variability in inflammatory status. Cox regression analysis was used to assess the association between hs-CRP variability and cancer risk after adjusting for potential confounding factors. The results demonstrated that a high CV of hs-CRP was significantly associated with reduced cancer risk [hazard ratio (HR), 0.84; 95% confidence interval (CI), 0.75-0.94]. Participants with high hs-CRP and low CV had a significantly increased risk of cancer (HR, 1.42; 95% CI, 1.18-1.70). In the stratified analysis of tumors at different sites, the association between hs-CRP variability and lung cancer risk was the most pronounced (HR, 0.77; 95% CI, 0.63-0.96). Sensitivity analyses confirmed the stability of the association between hs-CRP variability and cancer. In conclusion, higher hs-CRP variability was associated with lower cancer risk, particularly for lung cancer; however, these findings provide preliminary evidence and require validation in future studies.
SN - 1792-0981
SN - 1792-1015
ER -